| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Generate Biomedicines, Inc.$13.66
-0.67 (-4.76%)
C 50Pipeline Score Fair Value Biotech · Clinical
Market Cap
1.86 B
EPS
-
P/E Ratio
-
Value Trade
9.51 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
7.22 M
R&D Expenses
57.81 M
Operating CF
-80.39 M
Total Assets
625.74 M
Total Liabilities
110.94 M
Equity
514.80 M
D/E Ratio
12,345
-4.72 %
Week
16.24 %
1 Month
20.98 %
3 Month
20.98 %
6 Month
20.98 %
5 Year
20.98 %
All Time
Cash Data
Cash Position
516.64 M
Monthly Burn
26.80 M
Runway
17.1 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
393.01 K
52 Week Range
11 - 16.75
% held by Insiders
57.06 %
% held by Institutions
19.45 %
Enterprise Value
1.41 B
Total Shares
128.21 M
Short %
10.75 %
Float Shares
97.95 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
C50
Pipeline Score $1.9B
Pipeline ValueFair Value
Valuation Signal5
Drugs Scored1.0x
rNPV / MCap Top 76%
Micro Cap (rank 220 of 912)
Percentile RankGenerate Biomedicines, Inc. carries a moderate pipeline score (50/100), with $4.9B risk-adjusted pipeline value, led by GB-0895 in Severe Asthma (Phase 3), across $85B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GB-0895 Small molecule | Severe Asthma | Phase 3 | NCT07276724 | 58% | $4.4B | RECRUITING | 1,572 | VERY_FAST | B (66) | Dec 1, 2028 | MODERATE_RISK | LOW Jun 11, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GENB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GENB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GENBGenerate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
Generate Biomedicines, Inc. announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference scheduled for June 8, 2026. The event will feature a live webcast available on the company's investor website, with an archived replay to follow. Generate Biomedicines focuses on advancing programmable biology to create optimized therapeutics.
Read more →GENB▼ -11.2%on this news
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
Generate Biomedicines, Inc. reported its Q1 2026 financial results, highlighting advancements in its clinical pipeline. The company is progressing with Phase 3 trials for GB-0895 and expects to initiate patient dosing for GB-4362 in mid-2026. Despite a net loss of $61.7 million, the company has a strong cash position of $516.6 million.
Read more →GENBGenerate Biomedicines, Inc. Announces Pricing of Initial Public Offering
Generate Biomedicines, Inc. has announced the pricing of its initial public offering, offering 25 million shares at $16.00 each, aiming to raise $400 million. The IPO is set to close on March 2, 2026, with shares expected to begin trading on Nasdaq on February 27, 2026. Goldman Sachs and Morgan Stanley are leading the offering.
Read more →Competitive Position
How GENB ranks across every disease it competes inCompetitive Position is a premium feature
See how GENB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial